Updated Favorable histology Wilms tumor risk stratification: Rationale for future Children’s Oncology Group clinical trials
hosted by Dr. Jill Knera · StayCurrentMD
Part of
Wilms Tumor 20 items
Educational content from recorded physician discussions — not medical advice. Talk to your (or your child's) care team about your situation.
Video
Impact of Pulmonary Tumor Burden in Favorable Histology Wilms Tumor Outcomes: A Report From the Children's Oncology Group Study AREN053
1 min · Published Mar 2026
Video
Wilms Tumor Protocol Violations: 2018 Pediatric Surgery Practice Gap #3
Dr. Todd Ponsky · Published Jun 2019
Video
Wilms Tumor Protocol Violations: Practice Gap discussion at Update Course 2018
9 min · Published Aug 2018
Video
Social Determinants of Health Influence on Survival in Wilms Tumor, Neuroblastoma, and Hepatoblastoma
1 min · Published Jan 2026
Video
Long-Term Follow-Up of Surgical Outcomes for Patients With Wilms Tumor and Neuroblastoma
1 min · Published Feb 2026
Video
Wilms Tumor Rapid Fire: Update Course 2015
8 min · Published Nov 2015
Video
Pediatric Surgical Oncology Research Collaborative (PSORC): Studying Rare Pediatric Tumors
56 s · Published May 2026
Video
Update Course Rewind 2025: Hirschsprung + ARM: Rare but Real
1 min · Published May 2026
Video
Update Course Rewind 2025: Hirschsprung + ARM: Rare but Real
1 min · Published May 2026
Video
Pooling Patients to Study Rare Pediatric Tumors: An Introduction to PSORC
56 s · Published May 2026
Video
The fetal frontier: A review of current and emerging fetal therapies for genetic diseases
44 s · Published May 2026
Video
Indocyanine green assists with sentinel lymph node mapping in pediatric and adolescent patients
1 min · Published May 2026
What the experts said
Risk stratification for Wilms tumor has evolved many times over the years.
The Children's Oncology Group published updated risk stratification for patients with favorable histology Wilms tumor in Nature in June 2025.
The new risk stratification model includes biological and clinical features that were not in the first generation risk stratification.
The new model changes some of the older features or gets rid of them altogether.
Factors being added are loss of heterozygosity of 11P15, 1Q gain, and lymph node involvement.
Tumor nephrectomy weight is no longer included in the risk stratification.
The model modified how histology and age are used to stratify certain patients.
More changes are expected in the future as ongoing COG trials produce more results.